Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Viking Therapeutics Inc. (NASDAQ:VKTX) is a biotechnology company developing treatments that focus on metabolic ailments. The firm is currently developing a weight loss drug under the title VK-2735 that is designed to work on GLP-1 and GIP receptors. Viking Therapeutics Inc. (NASDAQ:VKTX)'s shares are up by 34% over the past year and are slightly down since Cramer discussed the firm in January 28 on Mad Money. One major reason behind the lackluster performance is a massive drop in August 2025 when Viking Therapeutics Inc. (NASDAQ:VKTX)'s stock closed 42% lower on the 19th. On that day, the firm released results of its mid-stage trial of the drug. The trial saw participants lose 12% of their body weight, while, according to media reports, investors were aiming for higher percentages. Viking Therapeutics Inc. (NASDAQ:VKTX)'s VK-2735 is a weight loss pill, and in late 2025, Novo Nordisk became the first to launch such a product. The performance also vindicated Cramer, as he had remarked
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735PR Newswire
- Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 2/11/26 - Miss
VKTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/10/26 - Form 4
- 2/11/26 - Form 10-K
- VKTX's page on the SEC website